i read the piece scott matusow had on ariad. He mentioned to expect a run up the rest of the year. upon the likelihood of an fda approval with ponatnib, what should follow is the big selloff.
Although I tend to agree with the selloff part, I do think that the sell off will be short lived. if 113 shows early promise before pona approval, once that approval for pona is accepted by the fda, it will literally be the game changer for ariad! There will be cash flow to fund other potential blockbuster drugs in development (which they do have!). But maybe more importantly for the stock price to rebound quickly from an initial selloff is, having secured fda approval, it will most likely grab the attention of big pharmas. With just the speculation of those companies wanting ariads technology, the price should propel substantially higher than what will be achieved (hopefully) from an fda approval of pona.
